[Fundamental and clinical studies on aztreonam in obstetrics and gynecology].
Fundamental and clinical studies on gynecological use of aztreonam (AZT), a new monobactam, were performed with following results. Following the intravenous administration of 1 g dose of AZT, the transfer of AZT to pelvic dead space exudate was good, in which the concentration of that was 14.9 micrograms/ml (2 hours), 15.3 micrograms/ml (3 hours) after injection. The transfer of AZT to serum of umbilical cord and amniotic fluid was excellent. In a clinical trial, AZT was given to 5 patients with obstetric and gynecological infections. The clinical efficacy was evaluated as excellent in 1 case and good in the other 4 cases. No adverse effects were observed in any of the patients treated with AZT.
D000328:Adult; D000368:Aged; D000653:Amniotic Fluid / Q000378:metabolism; D001398:Aztreonam / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D005122:Exudates and Transudates / Q000378:metabolism; D005260:Female; D005312:Fetal Blood / Q000378:metabolism; D005831:Genital Diseases, Female / Q000188:drug therapy*; D006801:Humans; D007263:Infusions, Parenteral; D008431:Maternal-Fetal Exchange; D008875:Middle Aged; D010388:Pelvis / Q000378:metabolism; D011247:Pregnancy; D011645:Puerperal Infection / Q000188:drug therapy*
D001398:Aztreonam